Literature DB >> 31143844

The power to predict with biomarkers: carbohydrate antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) serum markers in intrahepatic cholangiocarcinoma.

Manuel Jaklitsch1,2, Henrik Petrowsky1.   

Abstract

Entities:  

Year:  2019        PMID： 31143844      PMCID： PMC6509429          DOI： 10.21037/tgh.2019.03.06

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN： 2415-1289


× No keyword cloud information.
  5 in total

1.  Bioinformatic Prediction of Signaling Pathways for Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) and Its Role in Cholangiocarcinoma Cells.

Authors:  Doungdean Tummanatsakun; Tanakorn Proungvitaya; Sittiruk Roytrakul; Siriporn Proungvitaya
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

2.  Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection?

Authors:  Fei Ma; Yonglei Zhang; Liangqun Peng; Zhandong Zhang; Wei Yang; Junhui Chai; Bin Zhang; Sheqing Ji; Yawei Hua; Xiaobing Chen; Suxia Luo
Journal:  Ann Transl Med       Date:  2020-08

3.  A Novel Prognostic Scoring System of Intrahepatic Cholangiocarcinoma With Machine Learning Basing on Real-World Data.

Authors:  Zhizhen Li; Lei Yuan; Chen Zhang; Jiaxing Sun; Zeyuan Wang; Yu Wang; Xin Hao; Fei Gao; Xiaoqing Jiang
Journal:  Front Oncol       Date:  2021-01-20       Impact factor: 6.244

4.  Double-Negative α-Fetoprotein and Carbohydrate Antigen 19-9 Predict a Good Prognosis in Intrahepatic Cholangiocarcinoma: A Propensity Score Matching Analysis.

Authors:  Xiaoyun Zhang; Yongjie Zhou; Zhenru Wu; Wei Peng; Chuan Li; Lvnan Yan; Jiayin Yang; Tianfu Wen
Journal:  Clin Transl Gastroenterol       Date:  2021-11-09       Impact factor: 4.488

5.  Progression Patterns and Post-Progression Survival in Recurred Intrahepatic Cholangiocarcinoma Patients: A Novel Prognostic Nomogram Based on Multicenter Cohorts.

Authors:  Chongyu Zhao; Chaobin He; Jiawei Lu; Xin Huang; Cheng Chen; Xiaojun Lin
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.